 |
市場調査レポート
商品コード
1463266
デジタルバイオマーカーの世界市場規模、シェア、成長分析、タイプ別、臨床診療別、治療領域別、最終用途別 - 産業予測、2024～2031年Global Digital Biomarkers Market Size, Share, Growth Analysis, By Type, By Clinical Practice, By Therapeutic Area(Cardiovascular and metabolic disorders, Respiratory disorders), By End-Use - Industry Forecast 2024-2031 |
||||||
| デジタルバイオマーカーの世界市場規模、シェア、成長分析、タイプ別、臨床診療別、治療領域別、最終用途別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月08日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のデジタルバイオマーカーの市場規模は、2022年に約29億6,000万米ドルとなり、2023年の36億1,000万米ドルから上昇し、予測期間（2024年～2031年）のCAGRは21.9%で、2031年までには175億9,000万米ドルに達すると予測されています。
同市場は、スマートフォンの普及、新型ウェアラブルの導入、治療領域での応用拡大とともに、健康関連のモバイルアプリケーションや接続されたデジタル機器の急速な普及により、拡大が見込まれています。待望の承認は、心血管疾患の兆候を示す特定の不整脈の早期発見を含め、患者とそのヘルスケアプロバイダーに、心臓の健康に関するより深い洞察を与えます。その結果、デジタルバイオマーカー市場は大幅な急成長を遂げています。さらに、ヘルスケア部門は、デジタルバイオマーカーに関する研究の促進を目的とした金融・投資活動の活発化によって、予測期間中に成長を目の当たりにすることが期待されています。さらに、多くの医療技術企業がCOVID-19パンデミック対策にデジタルバイオマーカー技術を提供しており、市場拡大をさらに後押ししています。Medopadと国際的なパートナーとの間の協力関係などは、検証プロセスを迅速化し、呼吸器指標のような重要なデータポイントのデジタルバイオマーカーを特定し、COVID-19のリスクが高い個人をピンポイントで特定することを目的としており、その結果、市場に利益をもたらしています。さらに、デジタルバイオマーカーの範囲はスマートウォッチやアクティビティトラッカーにとどまりません。大手製薬会社は革新的なデジタルヘルス新興企業と提携し、この技術の採用を加速させ、デジタルバイオマーカーの領域で斬新なソリューションを強化することで、市場の成長を促進しています。COVID-19パンデミックがもたらす深刻な課題を認識している政府機関は、デジタルバイオマーカーに基づく医薬品開発に関心を示しています。デジタルバイオマーカーが提供する無数の利点にもかかわらず、データのプライバシー、信頼性、データの検証、オープンソースデータの不在に関する懸念など、特定の障害が市場の成長を阻害すると予想されます。しかし、予測期間中は競合の増加やシステムの利用拡大により、こうした課題は克服されるとみられます。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
デジタルバイオマーカーの世界市場：タイプ別
- 市場概要
- ウェアラブル
- モバイルベースのアプリケーション
- センサー
- その他
デジタルバイオマーカーの世界市場：臨床診療別
- 市場概要
- 診断用デジタルバイオマーカー
- デジタルバイオマーカーのモニタリング
- 予測および予後デジタルバイオマーカー
- その他（安全性、薬力学/反応性、感受性）
デジタルバイオマーカーの世界市場：治療領域別
- 市場概要
- 心血管および代謝障害（CVMD）
- 呼吸器疾患
- 精神障害
- 睡眠と運動の病気
- 神経学的障害
- 筋骨格障害
- その他（糖尿病、疼痛管理）
デジタルバイオマーカーの世界市場：最終用途別
- 市場概要
- ヘルスケア企業
- ヘルスケア提供者
- 支払者
- その他（患者、介護者）
デジタルバイオマーカーの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- ActiGraph LLC
- AliveCor Inc.
- Koneksa
- Altoida Inc.
- Amgen Inc.
- Biogen Inc.
- Empatica Inc.
- Vivo Sense
- IXICO plc
- Adherium Limited
- Neurotrack Technologies, Inc.
- Aural Analytic
- Huma
- Sonde Health, Inc.
- Clario
- Imagene AI
- Brainomix
- Kinsa Inc.
- Feel Therapeutics
- ResApp（Pfizer）
Global digital biomarkers market size was valued at around USD 2.96 billion in 2022 and is expected to rise from USD 3.61 billion in 2023 to reach a value of USD 17.59 billion by 2031, at a CAGR of 21.9 % over the forecast period (2024-2031).
The market is poised for expansion owing to the rapid adoption of health-related mobile applications and connected digital devices, alongside the increasing prevalence of smartphone usage, the introduction of novel wearables, and the broadening applications in therapeutic domains. The much-awaited approval is empowering patients and their healthcare providers with deeper insights into cardiac health, including the early detection of specific arrhythmias indicative of cardiovascular disease. Consequently, the market for digital biomarkers is experiencing a substantial growth surge. Moreover, the healthcare sector is expected to witness growth over the forecast period, fueled by heightened financial and investment activities aimed at expediting research on digital biomarkers. Additionally, numerous health technology companies have contributed their digital biomarker technologies to combat the COVID-19 pandemic, further driving market expansion. Collaborations, such as that between Medopad and international partners, aim to expedite the validation process, identify digital biomarkers for critical data points like respiratory indicators, and pinpoint individuals at higher risk for COVID-19, thus benefitting the market. Furthermore, the scope of digital biomarkers extends beyond smartwatches and activity trackers. Major pharmaceutical companies are teaming up with innovative digital health start-ups to accelerate the adoption of this technology and enhance novel solutions in the realm of digital biomarkers, thereby fostering market growth. Government organizations, acknowledging the profound challenges posed by the COVID-19 pandemic, are expressing interest in developing medications based on digital biomarkers. Despite the myriad advantages offered by digital biomarkers, certain obstacles, such as concerns regarding data privacy, reliability, data validation, and the absence of open-source data, are anticipated to impede market growth. However, during the forecast period, increasing competition and expanded utilization of these systems are expected to surmount these challenges.
Top-down and bottom-up approaches were used to estimate and validate the size of the global digital biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Digital Biomarkers Market Segmental Analysis
The global digital biomarkers market is segmented based on type, clinical practice, therapeutic area, end-use, and region. By type, the market is segmented into wearable, mobile based applications, sensors, and others. By clinical practice, the market is segmented into diagnostic digital biomarkers, monitoring digital biomarkers, predictive, and prognostic digital biomarkers, and others (safety, pharma co-dynamics/ response, susceptibility). By therapeutic areas, the market is segmented into cardiovascular and metabolic disorders (CVMD), respiratory disorders, psychiatric disorders, sleep & movement disease, neurological disorders, musculoskeletal disorders, and others (diabetes, pain management). By end-use, the market is segmented into healthcare companies, healthcare providers, payers, others (patient, caregivers). By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Drivers of the Global Digital Biomarkers Market
The increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is fueling the demand for digital biomarkers. These biomarkers play a crucial role in the early detection and management of these conditions.
Restraints in the Global Digital Biomarkers Market
The absence of definitive regulatory guidelines for digital biomarkers is impeding the growth of this market by creating uncertainty for investors and manufacturers alike.
Market Trends of the Global Digital Biomarkers Market
The growing popularity of wearables and mobile health apps among both consumers and healthcare providers is fueling the expansion of the digital biomarkers market. These technologies facilitate continuous and remote monitoring of patients, generating substantial amounts of data that can be leveraged to develop digital biomarkers.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Digital Biomarkers Market by Type
- Market Overview
- Wearable
- Mobile based Applications
- Sensors
- and Others
Global Digital Biomarkers Market by Clinical Practice
- Market Overview
- Diagnostic digital biomarkers
- Monitoring digital biomarkers
- Predictive and Prognostic digital biomarkers
- Other's (Safety
- Pharmacodynamics/ Response
- Susceptibility)
Global Digital Biomarkers Market by Therapeutic Area
- Market Overview
- Cardiovascular and metabolic disorders (CVMD)
- Respiratory disorders
- Psychiatric disorders
- Sleep & Movement Disease
- Neurological disorders
- Musculoskeletal disorders
- and Others (Diabetes
- Pain Management)
Global Digital Biomarkers Market by End-Use
- Market Overview
- Healthcare companies
- Healthcare Providers
- Payers
- and Others (Patient
- caregivers)
Global Digital Biomarkers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- ActiGraph LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AliveCor Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Koneksa
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Altoida Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Empatica Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vivo Sense
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IXICO plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adherium Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurotrack Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aural Analytic
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Huma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sonde Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clario
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Imagene AI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Brainomix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kinsa Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Feel Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ResApp (Pfizer)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
